Case Report: Interferon-γ Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome
Open Access
- 7 April 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12, 645124
- https://doi.org/10.3389/fimmu.2021.645124
Abstract
Background: The major histocompatibility complex (MHC) class II characterized by monocytes CD14+ expression of human leukocyte antigen receptors (HLA-DR), is essential for the synapse between innate and adaptive immune response in infectious disease. Its reduced expression is associated with a high risk of secondary infections in septic patients and can be safely corrected by Interferon-y (IFNy) injection. Coronavirus disease (COVID-19) induces an alteration of Interferon (IFN) genes expression potentially responsible for the observed low HLA-DR expression in circulating monocytes (mHLA-DR). Methods: We report a case of one-time INFy injection (100 mcg s.c.) in a superinfected 61-year-old man with COVID-19–associated acute respiratory distress syndrome (ARDS), with monitoring of mHLA-DR expression and clinical tolerance. Observations: Low mHLA-DR pretreatment expression (26.7%) was observed. IFNy therapy leading to a rapid increase in mHLA-DR expression (83.1%). Conclusions: Severe ARDS in a COVID-19 patient has a deep reduction in mHLA-DR expression concomitantly with secondary infections. The unique IFNy injection was safe and led to a sharp increase in the expression of mHLA-DR. Based on immune and infection monitoring, more cases of severe COVID-19 patients with low mHLA-DR should be treated by IFNy to test the clinical effectiveness.This publication has 25 references indexed in Scilit:
- Ready for Prime Time? Biomarkers in SepsisEmergency Medicine Clinics of North America, 2017
- Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016Intensive Care Medicine, 2017
- Review of the recombinant human interferon gamma as an immunotherapeutic: Impacts of production platforms and glycosylationJournal of Biotechnology, 2016
- Side Effects of Cytokines Approved for TherapyDrug Safety, 2014
- Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapiesCurrent Opinion in Immunology, 2013
- Interferon‐gamma inhibits healing post scald burn injuryWound Repair and Regeneration, 2012
- Low monocyte human leukocyte antigen-DR is independently associated with nosocomial infections after septic shockIntensive Care Medicine, 2010
- Sepsis biomarkers: a reviewCritical Care, 2010
- Clinical Use of Interferon‐γAnnals of the New York Academy of Sciences, 2009
- Monocytic HLA-DR expression in intensive care patients: Interest for prognosis and secondary infection prediction*Critical Care Medicine, 2009